Anticipating Mondelez International’s Upcoming Earnings: Key Insights to Watch

Avatar photo

Mondelez International’s Upcoming Earnings and Stock Performance Analysis

With a market capitalization of $88.3 billion, Mondelez International, Inc. (MDLZ) stands as a leader in the global snacking industry. Headquartered in Chicago, Illinois, this company boasts a diverse portfolio that includes iconic brands like Oreo, Ritz, LU, Clif Bar, and Tate’s Bake Shop. In the confectionery sector, Mondelez’s staples include well-known chocolates such as Cadbury Dairy Milk, Milka, and Toblerone. The company is scheduled to report its first-quarter earnings on Tuesday, April 29.

Analysts are predicting that MDLZ will report earnings of $0.66 per share on a diluted basis. This figure represents a significant decrease of 30.5% from the previous year’s $0.95 per share. However, it’s worth noting that Mondelez has exceeded Wall Street’s EPS estimates in three out of its last four quarterly reports.

For the entire fiscal year, analysts forecast MDLZ will report an EPS of $2.90, down 13.7% from last year’s $3.36. Nonetheless, projections indicate a recovery in EPS, expected to climb by 10.7% year-over-year, reaching $3.21 in fiscal 2026.

www.barchart.com

Over the past 52 weeks, MDLZ stock has underperformed relative to the broader market, declining 2.4%, while the S&P 500 ($SPX) has increased by 5.5%. Furthermore, it has also trailed the Consumer Staples Select Sector SPDR Fund (XLP), which saw an 11.4% increase in the same timeframe.

www.barchart.com

On April 4, Mondelez stock saw a rise of over 1%. This uptick occurred as investors shifted their focus to defensive sectors amid a broader market sell-off, favoring stable food and beverage companies like Mondelez.

Overall, analysts maintain a very bullish consensus on MDLZ, issuing a “Strong Buy” rating for the stock. From 25 analysts providing coverage, 15 recommend a “Strong Buy,” two suggest a “Moderate Buy,” seven recommend a “Hold,” and one advises a “Strong Sell.” Currently, MDLZ trades above its average target price of $67.88.


On the date of publication, Kritika Sarmah did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information, please view the Barchart Disclosure Policy here.

More news from Barchart

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

The free Daily Market Overview 250k traders and investors are reading

Read Now